MARLBOROUGH, Mass. — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b improves natural killer (NK) cell activity for adoptive cell therapy and may result in a more effective cell therapy for hematological malignancies will be presented at the 10th Immunotherapy of Cancer Conference (ITOC10), which will be held in Munich, Germany from March 21-23, 2024.
Presentation Details are as follows:
| Title: | Enhancing NK cell cytotoxicity against tumor cells with a novel self-delivering RNAi compound targeting Cbl-b |
| Poster Number: | P01.03 |
| Topic: | 01.Emerging concepts / New Agents |
| Presenting Author: | Melissa Maxwell |
| Date and Time: | 18:00 hrs Thursday, March 21, 2024 |
| 18:00-19:00 hrs Friday, March 22, 2024 | |
| Location: | Ludwig Maximilian University Campus Großhadern, |
| Lecture Room 3, Marchioninistrasse 15 | |
| 81377 Munich, Germany |
The poster presentation will be accessible in person and will also be available on March 21st, on Phio’s website.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Contact
Phio Pharmaceuticals Corp.
[email protected]
PR Contact
Michael Adams
Bridge View Media
[email protected]